ATE397922T1 - Lipidspiegel modulation mit steroiden und ppar- alpha agonisten - Google Patents
Lipidspiegel modulation mit steroiden und ppar- alpha agonistenInfo
- Publication number
- ATE397922T1 ATE397922T1 AT02707001T AT02707001T ATE397922T1 AT E397922 T1 ATE397922 T1 AT E397922T1 AT 02707001 T AT02707001 T AT 02707001T AT 02707001 T AT02707001 T AT 02707001T AT E397922 T1 ATE397922 T1 AT E397922T1
- Authority
- AT
- Austria
- Prior art keywords
- ppar
- steroids
- level modulation
- alpha agonists
- lipide level
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 abstract 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 abstract 1
- 230000000778 atheroprotective effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0107383.2A GB0107383D0 (en) | 2001-03-23 | 2001-03-23 | Lipid profile modulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397922T1 true ATE397922T1 (de) | 2008-07-15 |
Family
ID=9911465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02707001T ATE397922T1 (de) | 2001-03-23 | 2002-03-25 | Lipidspiegel modulation mit steroiden und ppar- alpha agonisten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050032761A1 (de) |
| EP (1) | EP1420769B1 (de) |
| JP (1) | JP2004528308A (de) |
| AT (1) | ATE397922T1 (de) |
| AU (1) | AU2002241160A1 (de) |
| CA (1) | CA2441834C (de) |
| DE (1) | DE60227080D1 (de) |
| DK (1) | DK1420769T3 (de) |
| ES (1) | ES2307729T3 (de) |
| GB (2) | GB0107383D0 (de) |
| PT (1) | PT1420769E (de) |
| WO (1) | WO2002076435A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258168B2 (en) | 2001-07-27 | 2007-08-21 | Enventure Global Technology L.L.C. | Liner hanger with slip joint sealing members and method of use |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| EP1854487A3 (de) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Kombinationspräparate welche einen 11-beta-Hydroxysteroiddehydrogenase Typ-1 Hemmer und einen Agonist des Glucocorticoidrezeptors enthalten |
| EP1615667A2 (de) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Kombinationspräparate welche einen 11-beta-hydroxysteroid-dehydrogenas typ-3 hemmer und einen glucocorticoid rezeptor agonist enthalten |
| ATE416761T1 (de) * | 2003-09-22 | 2008-12-15 | Onepharm Res & Dev Gmbh | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund |
| WO2006106052A1 (en) | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| WO2007058346A1 (ja) | 2005-11-21 | 2007-05-24 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| AU2007207055B2 (en) | 2006-01-18 | 2011-06-02 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-HSD1 inhibitors |
| JP2009531712A (ja) * | 2006-03-23 | 2009-09-03 | デ グスマン ブレイヤー、エメリタ | アポリポタンパク質フィンガープリント技術 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| DK2163543T3 (en) | 2007-05-18 | 2015-04-27 | Shionogi & Co | Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet |
| MX2011005037A (es) | 2008-11-21 | 2011-06-16 | High Point Pharmaceuticals Llc | Compuestos de adamantilo benzamida. |
| WO2011061749A2 (en) * | 2009-11-19 | 2011-05-26 | Ganga Raju Gokaraju | Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
| US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
| US9781909B2 (en) * | 2013-07-17 | 2017-10-10 | University Of Manitoba | Mito-Ob: a transgenic mouse model for obesity |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| US10226474B2 (en) * | 2017-01-09 | 2019-03-12 | Temple University—Of The Commonwealth Sytem Of Higher Education | Methods and compositions for treatment of non-alcoholic steatohepatitis |
| KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| AU2023273030A1 (en) | 2022-05-16 | 2024-11-07 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| JP2004502432A (ja) * | 2000-07-05 | 2004-01-29 | バイエル アクチェンゲゼルシャフト | ヒト１１β−ヒドロキシステロイドデヒドロゲナーゼ１様酵素の調節 |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
-
2001
- 2001-03-23 GB GBGB0107383.2A patent/GB0107383D0/en not_active Ceased
-
2002
- 2002-03-25 AT AT02707001T patent/ATE397922T1/de active
- 2002-03-25 JP JP2002574951A patent/JP2004528308A/ja active Pending
- 2002-03-25 PT PT02707001T patent/PT1420769E/pt unknown
- 2002-03-25 ES ES02707001T patent/ES2307729T3/es not_active Expired - Lifetime
- 2002-03-25 DE DE60227080T patent/DE60227080D1/de not_active Expired - Lifetime
- 2002-03-25 AU AU2002241160A patent/AU2002241160A1/en not_active Abandoned
- 2002-03-25 DK DK02707001T patent/DK1420769T3/da active
- 2002-03-25 GB GB0323962A patent/GB2390367B/en not_active Expired - Fee Related
- 2002-03-25 EP EP02707001A patent/EP1420769B1/de not_active Expired - Lifetime
- 2002-03-25 CA CA2441834A patent/CA2441834C/en not_active Expired - Fee Related
- 2002-03-25 WO PCT/GB2002/001457 patent/WO2002076435A2/en not_active Ceased
-
2003
- 2003-09-23 US US10/668,564 patent/US20050032761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1420769A2 (de) | 2004-05-26 |
| GB2390367A (en) | 2004-01-07 |
| CA2441834C (en) | 2011-01-25 |
| JP2004528308A (ja) | 2004-09-16 |
| DE60227080D1 (de) | 2008-07-24 |
| WO2002076435A2 (en) | 2002-10-03 |
| US20050032761A1 (en) | 2005-02-10 |
| GB0107383D0 (en) | 2001-05-16 |
| WO2002076435A3 (en) | 2004-03-18 |
| DK1420769T3 (da) | 2008-09-29 |
| PT1420769E (pt) | 2008-08-05 |
| EP1420769B1 (de) | 2008-06-11 |
| GB2390367B (en) | 2005-04-13 |
| CA2441834A1 (en) | 2002-10-03 |
| ES2307729T3 (es) | 2008-12-01 |
| GB0323962D0 (en) | 2003-11-19 |
| AU2002241160A1 (en) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60227080D1 (de) | Lipidspiegel modulation mit steroiden und ppar-alpha agonisten | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| BR0215405A (pt) | Composições e processos de uso de collajolie | |
| CY1107512T1 (el) | Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους | |
| ECSP055838A (es) | Formulaciones de deposito de liberacion controlada | |
| DK1292539T3 (da) | Mikroniseret bariumsulfat | |
| CY1112862T1 (el) | Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα | |
| MY144626A (en) | Semiconductor-nanocrystal/conjugated polymer thin films | |
| IL214325A (en) | Antibody against cmet, a drug that includes and uses it | |
| BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
| CY1108109T1 (el) | Χρηση cci-779 ως αντινεοπλασματικου παραγοντα | |
| BRPI0412029A (pt) | formulações para microprojeções revestidas contendo contra-ìons não-voláteis | |
| WO2002041843A3 (en) | Antiinflammation agents | |
| AR015451A1 (es) | Metodos y composiciones para blanquear los dientes | |
| DE69905170T2 (de) | Thiazolopyrimidinderivate | |
| BR9808858A (pt) | Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos | |
| CL2004000026A1 (es) | Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. | |
| DK1265911T3 (da) | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler | |
| CY1105009T1 (el) | Συνθεση καχαλαλιδης f | |
| NO20034139D0 (no) | Faste oralt-dispersible farmasöytiske formuleringer | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| BR0307017A (pt) | agentes hipnóticos sedativos de ação rápida para anestesia e sedação | |
| BR0210101A (pt) | Combinações antineoplásticas | |
| ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1420769 Country of ref document: EP |